How many drugs treat Hyperuricemia?

Drug Landscape tracks 8 marketed treatments for Hyperuricemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Hyperuricemia?

Most recent: Aloprim — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hyperuricemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hyperuricemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperuricemia (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hyperuricemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zurampic	LESINURAD	Ironwood Pharms Inc	Urate Transporter 1 Inhibitor	Solute carrier family 22 member 11	2015-01-01
Uloric	FEBUXOSTAT	Takeda	Xanthine Oxidase Inhibitor [EPC]	Xanthine dehydrogenase/oxidase	2009-01-01
Aloprim	ALLOPURINOL	Casper Pharma Llc	Xanthine Oxidase Inhibitor [EPC]	Xanthine dehydrogenase/oxidase	1966-01-01
Col-Probenecid	probenecid	Pfizer Inc.	probenecid	Carbonic anhydrase 9	1951-01-01
Benzbromaron	Benzbromaron	Amsterdam UMC, location VUmc		Eyes absent homolog 2, Eyes absent homolog 3, ATP-binding cassette sub-family G member 2
Uriadec	TOPIROXOSTAT	Senwa Kegaku Kenkyushp		ATP-binding cassette sub-family G member 2, Xanthine dehydrogenase/oxidase, Xanthine dehydrogenase/oxidase
Urece	DOTINURAD	Fuji Yakuhin		Solute carrier family 22 member 12
Adenuric	Adenuric	Pharmtechnology LLC		Flavin reductase (NADPH), ATP-binding cassette sub-family G member 2, Potassium voltage-gated channel subfamily H member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-13 — Aloprim · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hyperuricemia:

Cite this brief

Drug Landscape (2026). Hyperuricemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hyperuricemia. Accessed 2026-06-10.

Hyperuricemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing